Commission Implementing Regulation (EU) 2026/1421 of 30 June 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bensulfuron, benzovindiflupyr, chlorotoluron, clethodim, cycloxydim, cymoxanil, dazomet, deltamethrin, diclofop, fenazaquin, fluopicolide, hymexazol, lambda-cyhalothrin, MCPA, MCPB, metaldehyde, metsulfuron-methyl, paclobutrazol and tebuconazole
Allegato 1ANNEX
In vigore · versione del 21 lug 2026
The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:
1.Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘30 June 2028’; (2) in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘30 June 2028’; (3) in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘31 July 2028’; (4) in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘31 July 2028’; (5) in the sixth column, expiration of approval, of row 263, Cymoxanil, the date is replaced by ‘30 November 2027’; (6) in the sixth column, expiration of approval, of row 268, Tebuconazole, the date is replaced by ‘31 July 2028’; (7) in the sixth column, expiration of approval, of row 271, Bensulfuron, the date is replaced by ‘15 November 2027’; (8) in the sixth column, expiration of approval, of row 297, Fluopicolide, the date is replaced by ‘31 January 2029’; (9) in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 January 2029’; (10) in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 January 2029’; (11) in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘15 December 2027’; (12) in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘30 November 2029’; (13) in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘15 October 2028’; (14) in the sixth column, expiration of approval, of row 342, Fenazaquin, the date is replaced by ‘15 August 2028’; (15) in the sixth column, expiration of approval, of row 344, Diclofop, the date is replaced by ‘31 January 2029’; (16) in the sixth column, expiration of approval, of row 348, Paclobutrazol, the date is replaced by ‘31 January 2029’.
2.Part E is amended as follows: (1) in the sixth column, expiration of approval, of row 3, Metsulfuron-methyl, the date is replaced by ‘31 July 2029’; (2) in the sixth column, expiration of approval, of row 4, Benzovindiflupyr, the date is replaced by ‘2 January 2029’; (3) in the sixth column, expiration of approval, of row 5, Lambda-Cyhalothrin, the date is replaced by ‘31 January 2029’.